Business Wire

Armis Named ‘Outperformer’ and ‘Leader’ in GigaOm Radar Report for Operational Technology Security for Second Consecutive Year

24.6.2024 18:15:00 EEST | Business Wire | Press release

Share

Armis, the asset intelligence cybersecurity company, today announced that it has been named a Leader and Outperformer in the 2024 GigaOm Radar Report for Operational Technology (OT) Security. This is the second year running is recognized as a Leader in the field of OT Security, cementing its status as a mature platform solution providing proactive end-to-end security for cross-vertical organizations looking for a cohesive approach to OT Security management.

Armis scored multiple 5/5 perfect scores showcasing Armis’ customer-centric vision to deliver OT security built on deep asset context, proactive threat intelligence and total vulnerability management. From cost and ease of use to scalability and flexibility and certification, Armis was recognized for being built for smooth deployment in OT environments.

“The on-going development of the Armis Centrix™ platform has enabled us to offer complete end to end OT security management from complete visibility, vulnerability remediation and management through to advanced AI threat detection,” said Yevgeny Dibrov, CEO and Co-founder of Armis. “I am grateful to GigaOm for recognizing, not just our leadership position, but also awarding us 'Outperformer status', praising the developments we have made this past year.”

The GigaOm Radar is a thoroughly comprehensive technology analysis of OT security solutions on the market today, focusing on the latest innovation and critical capabilities that customers need to protect their entire environment. It also benchmarks current solutions and is able to effectively track how OT/ICS security has evolved in order to stay ahead of modern threat actors and attack vectors.

“Armis has excelled in rapidly advancing its technological offerings and has notably enhanced its threat detection capabilities over the past year, pushing the boundaries of innovation in OT security,” said Chris Ray, Research Analyst at GigaOm. “Armis is positioned as a Platform Play because it offers an extensive and integrated security platform capable of addressing multiple OT security concerns, making it well-suited for organizations seeking comprehensive solutions. It is classified as Innovative due to its aggressive approach in introducing new features and capabilities, which highlights its commitment to staying ahead in technology advancements. Armis has achieved Leader status thanks to its effective market penetration and the robustness of its security solutions.”

Within the GigaOm Radar for OT Security, Armis Centrix™ is recognized for:

  • Asset Discovery - Armis' automated asset discovery feature received a 5/5 score for surpassing traditional methods by incorporating passive network discovery, active asset querying techniques, integration-based approaches, and asset profiling. This thorough strategy ensures precise identification of all devices, managed or unmanaged, granting organizations a complete view of their network landscape.
  • Dynamic Network Segmentation - Additionally, Armis received a 5/5 score for its dynamic network segmentation, utilizing knowledge of VLANs, subnets, and wireless networks to create device segments as the dynamic attack surface requires, and provide insights into architectural changes for more secure environments.
  • Managing Complex, Converged Environments - Armis demonstrated proficiency in managing diverse environments, including the OT, IT, IoT, and medical sectors. Armis Centrix™ showcased strong adherence to industry standards and regulatory requirements, scoring a 5/5 for business certification criterion thus instilling trust and confidence in its customers. Notable certifications include FedRAMP, DoD Impact Level 4, ISO 27001, ISO 28018, and SOC 2 type 2.
  • Next-Generation AI Threat Detection - With the addition of actionable threat intelligence capabilities this year Armis displayed huge growth in AI technologies for threat detection. Scoring a 5/5, Armis was applauded for using AI to identify attacks still in the formulation stage as well as pinpointing anomalous behavior, unusual activities, malicious code, and other threats in real time. Armis integrates with SIEM, SOAR, XDR, and ASM solutions, ensuring comprehensive coverage and visibility across the entire attack surface.
  • Integration with IT security systems - Ensuring coordinated security efforts across both IT and OT environments. This convergence enhances the overall cybersecurity posture of an organization, addressing complex, multifaceted threats that span the IT-OT divide.
  • Providing visualization of OT asset relationships - Offering best-in-class dashboards and Purdue modeling to represent how OT assets connect and interact within an organization's network. This visibility is essential for understanding potential pathways of cyber threats and optimizing security responses.

“Armis offers a comprehensive suite of security features well-suited for SMBs, large enterprises, and public sector organizations,” continued Ray. “Leaders like Armis demonstrate robust platform capabilities with wide-reaching security features, making them stalwarts in the industry.”

The 2024 GigaOm Radar Report is a valuable resource for organizations aiming to enhance their OT security posture. It offers a thorough overview of the OT security market and highlights the leading vendors in the space. To learn more, read the Armis blog highlighting key findings from this year’s report here.

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624790874/en/

Contacts

Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye